About Traferox

Founded by transplantation and medical device innovators, including the surgeon developers of the first successful ex-vivo lung assessment and 10°C organ preservation technique, Traferox was built around the goal of developing innovative products to improve transplantation.

Board of Directors

Our Mission

Revolutionizing organ transplantation, grounded in world-class science

Our Values

At Traferox, we are committed to:

Prioritizing science and data

Delivering results

Medical team preparing donor lungs for transplantation in a hospital setting

Today we manufacture, commercialize, and take pride in:

The only device that truly embodies the Toronto Technique for ex vivo lung perfusion and assessment

Our novel devices that are designed to improve preservation and deliver better quality organs to transplant centers

Our outstanding clinical results

  • High rates of organ acceptance for marginal organs1
  • Low rates of severe primary graft dysfunction at 72 hours2,3
  • Shorter transplantation waitlist times2

Tomorrow we will continue to build on this foundation, with the ultimate goal of modifying allograft organ characteristics to:

Reduce the risk of rejection

Reduce complications associated with organ transplantation and immunosuppression

Improve longevity of donor grafts and survival overall

Our History

Shaf Keshavjee and Marcelo Cypel standing next to a TorEx Lung Perfusion System

1986

First successful double lung transplant in the world


Lung storage solution developed

2008

First clinical EVLP case

2012

Published clinical EVLP experience—excellent results with marginal lungs

2019

10°C mechanism for organ preservation defined

2021

Traferox is founded

2022

First clinical EVLP case performed using the TorEx Lung Perfusion System

2023

AATS guidelines published highlighting 10°C as a method for organ preservation

2023-24

Adoption of TorEx in new centers

2024

>150 EVLPs on TorEx


>100 transplants from TorEx-assessed lungs (65%)

2025

X°Port Lung Preservation System cleared by the FDA

Contact Us

Have a question or want to learn more? Fill out the form below and a member of our team will be in touch shortly.

    By submitting this form, you agree to the processing of your personal data for the purpose of responding to your inquiry. For more information on how we handle your data, please review our Privacy Policy.


    1. Peel, J.K., Pullenayegum, E.M., Naimark, D., Aversa, M., Liu, M., Del Sorbo, L., Barrett, K., Sander, B. and Keshavjee, S., 2023. Evaluating the impact of ex vivo lung perfusion on organ transplantation: a retrospective cohort study. Annals of Surgery, 278(2), pp.288-296. ↩︎
    2. Hoetzenecker, K., Ali, A., de la Cruz, J.C.C., Schwarz, S., Carrasco, S.C., Roman, A.R., Aladaileh, M., Benazzo, A., Jaksch, P., Wakeam, E. and Aversa, M., 2025. Prolonged Preservation of up to 24 Hours at 10° C Does Not Impact Outcomes after Lung Transplantation. Annals of Surgery, 281(4), pp.664-670. ↩︎
    3. Yeung, J.C., Krueger, T., Yasufuku, K., de Perrot, M., Pierre, A.F., Waddell, T.K., Singer, L.G., Keshavjee, S. and Cypel, M., 2017. Outcomes after transplantation of lungs preserved for more than 12 h: a retrospective study. The Lancet Respiratory Medicine, 5(2), pp.119-124. ↩︎